Research Radar

New PubMed studies on repurposed drugs and natural compounds in cancer — summarized in plain language and reviewed by a person before posting.

How to read this page. These studies are automatically collected from PubMed and summarized by AI from the abstract, then reviewed by a human before publishing. Each summary describes only what that study reported — most are early lab, animal, or small human studies, and findings often conflict. This is educational information, not medical advice, and not a recommendation to take anything. Always talk with your oncologist.

Topic tags. Each study is filed under its main topic. Anticancer studies are the default; these tags flag the other dimensions:

Safety — Safety & interactionsAbsorption (PK) — How it's absorbed (PK)Formulation — Formulation & deliverySupportive care — Symptom & supportive careMetabolism — Metabolism & pathwaysTrial — Clinical trialMechanism — Biomarker & mechanism

Showing studies that mention “ovarian carcinosarcoma”.

Human onlyPositive outcomesSafety signalsTrials2 of 4 studies

ReviewInconclusiveLimited evidenceTier 4 · clinical

Frontiers of Ovarian Carcinosarcoma

Current treatment options in oncology · Dec 2023 · narrative review

ovarian carcinosarcomaovarian cancer

This review summarizes what is known about ovarian carcinosarcoma, a rare and aggressive ovarian cancer. It discusses risk factors, prognostic markers, and current treatment approaches such as surgery followed by platinum-based chemotherapy, while noting that immunotherapy and HRD testing may be useful in some patients. The article does not report new experimental results from a trial or laboratory study.

Key findings

Ovarian carcinosarcoma is described as rare and aggressive, with median overall survival under 2 years.
Poor prognostic factors include advanced stage, older age, lymph node metastasis, suboptimal cytoreduction, heterologous histology, and increased VEGF, p53, and WT1 expression.
Main treatment approach is cytoreductive surgery followed by platinum-based chemotherapy.
Immunotherapy is described as promising, and HRD testing may help personalize therapy.

Limitations: Narrative review rather than original research.; No new patient cohort, control group, or quantitative treatment effect data reported in the abstract.; Most evidence discussed is from case reports and small studies.; The abstract does not specify which therapies or biomarkers were evaluated in detail..

Provides an overview of ovarian carcinosarcoma epidemiology, prognosis, and treatment options rather than testing a specific compound.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human trialTrialReported positiveStrong evidenceTier 4 · clinicaln = 536

Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Mar 2022 · randomized phase III trial

Carboplatin Paclitaxel Ifosfamideuterine carcinosarcomaovarian carcinosarcoma

This randomized phase III study compared paclitaxel plus carboplatin with paclitaxel plus ifosfamide in adults with uterine or ovarian carcinosarcoma. In uterine carcinosarcoma, paclitaxel plus carboplatin was not inferior to the ifosfamide regimen and had longer median overall survival and progression-free survival. Toxicities were broadly similar, although some side effects differed between the two groups.

Reported effects: median OS 37 mo, p P < .01 for noninferiority, P > .1 for superiority, n=449 · HR 0.87 [0.7–1.075], p P < .01 for noninferiority, P > .1 for superiority, n=449 · +4 more

Studied with: carboplatin, ifosfamide.

Key findings

In uterine carcinosarcoma, paclitaxel plus carboplatin was not inferior to paclitaxel plus ifosfamide for overall survival.
Median overall survival was 37 versus 29 months in uterine carcinosarcoma.
Median progression-free survival was 16 versus 12 months in uterine carcinosarcoma.
Toxicities were similar overall, with more hematologic toxicity in the paclitaxel-carboplatin arm and more confusion and genitourinary hemorrhage in the paclitaxel-ifosfamide arm.
In ovarian carcinosarcoma, paclitaxel plus carboplatin had numerically longer survival outcomes, but the differences were not statistically significant.

Limitations: Primary analysis was focused on uterine carcinosarcoma; ovarian carcinosarcoma results had limited precision.; The abstract reports noninferiority and superiority p-values but does not provide full confidence intervals for progression-free survival.; Toxicity details are summarized only briefly in the abstract..

This study evaluates chemotherapy regimens in carcinosarcoma, a cancer setting, with direct survival and toxicity outcomes.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text